… efficacy the novel anticoagulants are required. New agents like enoxaparin, apixaban and
… [1] Betrixaben is approved by FDA in class of clotting factor Xa inhibitor. Betrixaban became …

… In this randomised, double-blind, phase 2 dose-finding study, we compared asundexian
20 mg or 50 mg once daily with apixaban 5 mg twice daily in patients aged 45 years or older …

… new agents, this article describes the unmet needs in oral anticoagulation therapy, explains
why FXI is a promising target for new oral … For example, rivaroxaban and apixaban were less …

The severe coronavirus disease 2019 (COVID-19) is associated with coagulopathy.
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and factor Xa (…

… However, apixaban significantly increased bleeding time compared to aspirin and ticagrelor
… asundexian, an oral, direct, potent, and selective FXIa inhibitor, represents a novel type of …

… -Liquid Anti-Xa assay using calibrator kits for apixaban and … the STA-Liquid Anti-Xa assay
for apixaban, rivaroxaban, and … their similar molecular weights (apixaban, 459.5; rivaroxaban, …

… of apixaban, a direct factor Xa (FXa) inhibitor approved for multiple indications. Eight healthy
subjects were randomized 3:1 (apixaban:… received 5 mg of oral apixaban or placebo. Blood …

… , selective oral anticoagulants that target thrombin and factor Xa (direct oral Xa inhibitor, DXaI)
… In the present study, the RITG for apixaban did not significantly fluctuate between the peak …

… of more specific, Direct Oral Anticoagulants (DOACs) 3 . Three commonly prescribed DOACs,
rivaroxaban, apixaban, and edoxaban, are factor Xa (FXa) inhibitors 4,5 and have shown a …

… Anti-Xa assays can estimate anticoagulant effect for specific FXaI's. The aim of this study was
to characterize anti-Xa levels in patients taking apixaban or … anti-Xa levels for apixaban and …